Springer in deal to buy Wolters Kluwer pharma-related journals

Share this article:

Wolters Kluwer reached an agreement to sell its pharma-related marketing and publishing services unit to Springer Science+Business Media, the firms said today.

The sale represents about 35% of Wolters Kluwer's pharma-related assets, based on 2010 revenue, Wolters Kluwer said, and is subject to regulatory approvals. Marketing and publishing services (MPS) employs 450 people globally.

In a statement, Derk Haank, CEO of Springer Science+Business Media, called the MPS content a “perfect complement to our existing portfolio” and said it will allow Springer to expand its science, technology and medicine operations “not only in the Americas and Asia-Pacific regions, but also in parts of Europe where we do not yet have offices.”

MPS has main offices in New Zealand, the UK, US and Italy. Its Adis unit publishes 24 scientific journals and newsletters aimed at those working in drug therapy and pharmacology. The VisionCare Group publishes another  six eye-related publications. MPS also houses the Adis R&D Insight drug development database and the inScience Communications medical communications agency, among other services sold to pharma and academic customers.

In July Wolters Kluwer announced its plan to divest the Pharma Solutions business unit as part of a strategic decision to focus on point-of-care tools and professional content. The firm is in separate discussions for the analytics part of the unit, including its two main brands—inThought  pipeline analysis tools and the Source pharmaceutical online dashboard.

“We are currently in the discussion phase on this transaction and until a deal is complete, healthcare analytics will remain part of Wolters Kluwer Health & Pharma Solutions,” said Robert Dekker, VP of communications for that division.

In 2010 the Health & Pharma Solutions division of Wolters Kluwer, which includes Pharma Solutions, generated €816 million ($1.1 billion) in total revenue, including both pharma and non-pharma sales.

Wolters Kluwer said it will use proceeds from the sale to reduce debt levels, in line with previous objectives.

Share this article:

Email Newsletters

More in News

AstraZenca beefs up respiratory portfolio

AstraZenca beefs up respiratory portfolio

AstraZeneca has made an $875-million move to beef up its respiratory pipeline by making Almirall's lineup its own.

Amgen Q2 sales rise, company to lay off up to 2,900

Amgen Q2 sales rise, company to lay off ...

The majority of the layoffs will be in the US.

Doctors want to know how CMS plans to display Sunshine payment data

Doctors want to know how CMS plans to ...

Physician and industry trade groups are asking CMS to explain how context will be provided to the general public around the dollar sums drugmakers ascribe to doctors for things like ...